Harmful impact of radioactive iodine (I131) therapy on hematological parameters in thyroid disease patients
DOI:
https://doi.org/10.59736/IJP.23.04.975Keywords:
Beta Rays, Iodine Radioisotopes, Hematological Parameters, Reactive oxygen speciesAbstract
Radioactive Iodine-131 is used to treat benign and malignant hyperthyroid patients. It is concentrated in thyroid tissue when taken orally. It destroys thyrocytes by omitting beta rays and also by producing reactive oxygen species (ROS). As it circulates through the blood stream, I131 causes direct harm to blood cells through beta radiation and indirect harm by producing free radicals. The study aims to investigate damaging effects of I131 on hematological parameters in patients with thyroid diseases.
Methods: A total of 100 hyperthyroid patients were recruited and split into four groups: male low-dose, female low-dose, male high-dose and female high-dose groups depending on their I131 dosage. Health professionals at PINUM Cancer Hospital Faisalabad administered I131, provided by the Pakistan Atomic Energy Centre Islamabad, to the patients. Hematological markers were evaluated prior as well as after I131 therapy.
Results: Following I131 therapy, total leukocyte count remained stable but the absolute lymphocyte count (ALC), RBCs count and platelets counts declined significantly within two weeks. ALC decreased 41.7%, and platelets dropped by 25% whereas RBCs displayed a reduction of 10%. Gender wises the decline in ALC was same in both genders but in platelets count the decline was higher in males while the decline in RBCs count was higher in females. Neutrophils presented hyper-segmentation of chromatin while cytoplasmic vacuolation and micronuclei formation were seen in lymphocytes.
Conclusions: Radioiodine therapy has the damaging effects on blood cells and causes a significant decline in lymphocytes, RBC and platelets counts. I131 also exhibited genotoxic effect on neutrophils and lymphocytes.
References
Pizzato M, Li M, Vignat J, Laversanne M, Singh D, La Vecchia C, et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 2022;10(4):264-72.
Lamartina L, Leboulleux S, Borget I, Schlumberger M. Global thyroid estimates in 2020. Lancet Diabetes Endocrinol. 2022;10(4):235-6.
Bukhari SI, Ali G, Memom MY, Sandeelo N, Alvi H, Talib A, et al. Prevalence and predictors of thyroid dysfunction amongst patients with type 2 diabetes mellitus in Pakistan. J Fam Med Prim Care. 2022;11(6):2739-43.
Ullah F, Ali SS, Tahir H. Clinical spectrum of thyroid disorders: an experience at a tertiary care hospital in Peshawar. Pak J Med Res. 2022;61(2):56-62.
Jahan S, Rouf A, Aziz S, Ateeq M. Thyroid disorders: spectrum of thyroid disorders, an experience in Gujranwala region of Punjab. Prof Med J. 2018;25(5):691-5.
Shim SR, Kitahara CM, Cha ES, Kim SJ, Bang YJ, Lee WJ. Cancer risk after radioactive iodine treatment for hyperthyroidism: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(9): e2125072.
Yang L, Ma J, Lei P, Yi J, Ma Y, Huang Z, et al. Advances in antioxidant applications for combating ¹³¹I side effects in thyroid cancer treatment. Toxics. 2023;11(6):529.
Signore A, Campagna G, Marinaccio J, de Vitis M, Lauri C, Berardinelli F, et al. Analysis of short-term and stable DNA damage in patients with differentiated thyroid cancer treated with ¹³¹I in hypothyroidism or with recombinant human thyroid-stimulating hormone for remnant ablation. J Nucl Med. 2022;63(10):1515-22.
Duskin-Bitan H, Leibner A, Amitai O, Diker-Cohen T, Hirsch D, Benbassat C, et al. Bone-marrow suppression in elderly patients following empiric radioiodine therapy: real-life data. Thyroid. 2019;29(5):683-91.
Boucai L, Ptashkin RN, Levine RL, Fagin JA. Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: a prospective study. Clin Endocrinol (Oxf). 2023;99(1):122-9.
Lee Y, Chung CH, Lin LF, Chiu CH, Chen YF, Chang CF, et al. Radioactive iodine treatment for thyroid cancer patients increases the risk of long-term gastrointestinal disorders: a nationwide population-based cohort analysis. Cancers (Basel). 2022;14(10):2505.
Berta DM, Teketelew BB, Cherie N, Tamir M, Abriham ZY, Ayele Angelo A, et al. Effect of radioactive iodine therapy on hematological parameters in patients with thyroid cancer: systematic review and meta-analysis. Front Endocrinol (Lausanne). 2025; 16:1562851.
Liu H, Chen Q, Liu B, Wang J, Chen C, Sun S. Blood profiles in the prediction of radioiodine-refractory papillary thyroid cancer: a case–control study. J Multidiscip Healthc. 2023; 16:535-46.
Khandaker MU, Hassanpour M, Khezripour S, Rezaei MR, Bazghandi A, Hassanpour M, et al. Investigation of the effect of ¹³¹I on blood parameters for thyroid cancer treatment. Radiat Phys Chem. 2023; 208:110897.
Burcak PS, Fatma NCS, Ali TA, Ozdemir E, Aydin C, Topaloglu O, et al. Hematological changes before and after radioactive iodine therapy. Endocr Abstr. 2021.
Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343-421.
Larkin A, Millan E, Noz M, Wagner S, Friedman K, Blum M. Radioactivity of blood samples taken from thyroidectomized thyroid carcinoma patients after therapy with ¹³¹I. Thyroid. 2011;21(9):1009-12.
Dini V, Salvatori M, Belli M, Lago ME, Nosdeo A, Dambra DP, et al. Changes in radiosensitivity to gamma-rays of lymphocytes from hyperthyroid patients treated with I-131. Int J Mol Sci. 2022;23(17):10156.
Sönmez B, Bektaş Ö, Erkut N, Sönmez M. Assessment of long-term hematologic effects in differentiated thyroid cancer patients treated with radioactive iodine. Turk J Hematol. 2021;38(4):306-12.
Demir AN, Kara Z, Sulu C, Uysal S, Zulfaliyeva G, Atar OA, et al. The effect of radioiodine therapy on blood cell counts in patients with differentiated thyroid cancer. Hormones (Athens). 2023;22(4):595-602.
Rui Z, Wu R, Zheng W, Wang X, Meng Z, Tan J. Effect of ¹³¹I therapy on complete blood count in patients with differentiated thyroid cancer. Med Sci Monit. 2021;27: e929590.
Yi W, Kim BH, Kim M, Ryang SR, Jang MH, Kim JM, et al. Short-term bone marrow suppression in differentiated thyroid cancer patients after radioactive iodine treatment. Endocr J. 2020;67(12):1193-8..
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Imran Shahid, Hira Mubeen, Allah Rakha
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
